Online inquiry

IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13649MR)

This product GTTS-WQ13649MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13649MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5792MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ7901MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK-249320
GTTS-WQ12993MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ10401MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY2127399
GTTS-WQ623MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ1090MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-838
GTTS-WQ14358MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ11412MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-8897
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW